Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics
Tóm tắt
Objective Selecting patients for phase 1 studies remains challenging. Given the lack of clear and reliable guidance for the estimation of life expectancy, we retrospectively assessed predictive factors of early death (within 90 days following inclusion) among these patients. Methods Two hundred fifty-seven consecutive cancer patients enrolled in phase I studies investigating cytotoxics at Oscar Lambret Cancer Center and Institut Claudius Regaud were included in the development database. Univariate and multivariate analyses (logistic regression model) were undertaken to determine the prognostic factors. A probability tree described the rate of early death in the different prognostic subgroups. This prognostic model was then evaluated on a second independent cohort of 128 patients treated at Léon Bérard Cancer Center. Results The median overall survival was 8.4 months in the dataset population, and the rate of early death was 15%. In multivariate analysis, the two prognostic factors for early death were albumin <38 g/l (OR = 5.21) and lymphocytes <700/mm3 (OR = 3.88). According to these two parameters, three prognostic subgroups were defined with early death rates of, respectively, 8/121 (6%), 19/119 (16%) and 13/17 (76%). In the validation dataset, the rates of early death according to three prognostic groups were 13/68 (19%), 20/57 (35%) and 3/3 (100%), respectively. Conclusion We do not recommend the enrolment of patients with albumin level below 38g/l and lymphocytes count below 700/mm3, in phase 1 trial investigating cytotoxics. Our model is helpful to discriminate “patients with reasonable life expectancy” as defined in most phase 1 protocols.
Tài liệu tham khảo
Grunwald HW (2007) Ethical and design issues of phase 1 clinical trials in cancer patients. Cancer Invest 25:124–126 doi:10.1080/07357900701225331
Kurzrock R, Benjamin RS (2005) Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med 352:930–932 doi:10.1056/NEJMe058007
Dillman RO, Koziol JA (1992) Phase I cancer trials: limitations and implications. Mol Biother 4:117–121 doi:10.1007/BF02171756
Lipsett MB (1995) On the nature and ethics of phase I trials. J Clin Oncol 13:1049–1051
Roberts TG, Goulard BH, Squitieri L et al (2004) JW. Trends in the risk and benefits to patients with cancer participating in phase 1 clinical trial. JAMA 292:2130–2140 doi:10.1001/jama.292.17.2130
Agrawal M, Emanuel EJ (2003) Ethics of phase 1 oncology studies: re-examining the arguments and data. JAMA 290:1075–1082 doi:10.1001/jama.290.8.1075
Daugherty CK, Ratain HJ, Grochowski E et al (1995) Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol 13:1062–1072
Bachelot T, Ray-Coquard I, Catimel G et al (2000) Multivariate analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol 11:151–156 doi:10.1023/A:1008368319526
Janisch L, Mick R, Schilsky RL et al (1994) Prognostic factors for survival in patients treated in phase I clinical trials. Cancer 74:1965–1973 doi:10.1002/1097-0142(19941001)74:7<1965::AID-CNCR2820740723>3.0.CO;2-1
Yamamoto N, Tamura T, Fukuoka M et al (1990) Survival and prognostic factors in lung cancer patients treated in phase I trials: Japanese experience. Int J Oncol 15:737–741
Han C, Braybrooke JP, Delplanque G et al (2003) Comparison of prognostic factors in patients in phase 1 trials of cytotoxic drugs versus new non cytotoxic agents. Br J Cancer 89:1166–1171 doi:10.1038/sj.bjc.6601218
Arkenau HT, Olmos D, Ang JE et al (2008) Clinical outcome and prognosis factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer 98:1029–1033 doi:10.1038/sj.bjc.6604218
Penel N, Vanseymortier M, Bonneterre ME et al (2008) Prognostic factors among cancer patients with good performance status screened for phase I trials. Invest New Drugs 26:53–58 doi:10.1007/s10637-007-9088-x
Ray-Coquard I, Ghesquiere H, Bachelot T et al (2001) Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br J Cancer 85:816–822 doi:10.1054/bjoc.2001.2011
Claude L, Perol D, Ray-Coquard I et al (2005) Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma. Radiother Oncol 76:334–339 doi:10.1016/j.radonc.2005.06.004
Borg C, Ray-Coquard I, Philip I et al (2004) CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients cancer. Cancer 101:2675–2680 doi:10.1002/cncr.20688
Morris JA, Gardner MJ (1988) Calculating confidence intervals for relative risks (odd ratios) and standardised ratios and rates. BMJ 296:1313–1316
Heinze G, Schemper M (2002) A solution to the problem of separation in logistic regression. Stat Med 21:2409–2419 doi:10.1002/sim.1047
Lemeshow S, Hosner DW (1982) A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 115:92–106
Penel N, Neu JC, Clisant S et al (2007) Risk factors for early cathter-related infections in cancer patients. Cancer 110:1586–1592 doi:10.1002/cncr.22942
Seve P, Ray-Coquard I, Trillet-Lenoir V et al (2006) Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer 107:2668–2670 doi:10.1002/cncr.22300
Coates RJ, Clark WS, Eley JW et al (1990) Race, nutritional status, and survival from breast cancer. J Natl Cancer Inst 82:1684–1692 doi:10.1093/jnci/82.21.1684
Liu SA, Tsai WC, Wong YK et al (2006) Nutritional factors and survival of patients with oral cancer. Head Neck 28:998–1007 doi:10.1002/hed.20461
Van Glabbeke M, Verweij J, Casali PG et al (2005) Initial and late resistance to imatinib in advanced gastrointestinal stroma tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer- Italian Sarcoma Group- Australasian Gastrointestinal Trials Group Study. J Clin Oncol 23:5795–5804 doi:10.1200/JCO.2005.11.601
Walsh SR, Cook EJ, Goulder F (2005) Neutrophil–lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 91:181–184 doi:10.1002/jso.20329
Penel N, Fournier C, Clisant S et al (2004) Cause of fever and value of C-reactive protein and procalcitonin in differentiating infections from paraneoplastic fever. Support Care Cancer 12:593–598 doi:10.1007/s00520-004-0602-9
Ribas A, Camacho LH, Lopez-Berestein G et al (2005) Antimour activity in melanoma and anti-self response in a phase 1 trial with the anticytotoxic T-lymphocytes-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 23:8968–8977 doi:10.1200/JCO.2005.01.109
Odenike OM, Larson RA, Gajria D et al (2008) Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs 26:233–239 doi:10.1007/s10637-008-9115-6
Chan E, Mulkerin D, Rothenberg M et al (2008) A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. Invest New Drugs 26:241–247 doi:10.1007/s10637-008-9118-3
Baetz T, Einsenhauer E, Siu L et al (2007) A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours. Invest New Drugs 25:217–225 doi:10.1007/s10637-006-9021-8
Sanborn SL, Gibbons J, Krishnamurthi S et al (2009) Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors. Invest New Drugs (in press)
Michael M, Gibbs P, Smith R et al (2009) Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer. Invest New Drugs (in press)
Decoster G, Stein G, Holdener EE (1990) Response and toxic deaths in phase I clinical trials. Ann Oncol 1:175–181
Von Hoff DD, Turner J (1991) Response rates, duration of response and dose response effects in phase I studies. Invest New Drugs 9:115–121